| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COVA1 |
| Uniprot No | Q16206 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-610aa |
| 氨基酸序列 | MQRDFRWLWVYEIGYAADNSRTLNVDSTAMTLPMSDPTAWATAMNNLGMAPLGIAGQPILPDFDPALGMMTGIPPITPMMPGLGIVPPPIPPDMPVVKEIIHCKSCTLFPPNPNLPPPATRERPPGCKTVFVGGLPENGTEQIIVEVFEQCGEIIAIRKSKKNFCHIRFAEEYMVDKALYLSGYRIRLGSSTDKKDTGRLHVDFAQARDDLYEWECKQRMLAREERHRRRMEEERLRPPSPPPVVHYSDHECSIVAEKLKDDSKFSEAVQTLLTWIERGEVNRRSANNFYSMIQSANSHVRRLVNEKAAHEKDMEEAKEKFKQALSGILIQFEQIVAVYHSASKQKAWDHFTKAQRKNISVWCKQAEEIRNIHNDELMGIRREEEMEMSDDEIEEMTETKETEESALVSQAEALKEENDSLRWQLDAYRNEVELLKQEQGKVHREDDPNKEQQLKLLQQALQGMQQHLLKVQEEYKKKEAELEKLKDDKLQVEKMLENLKEKESCASRLCASNQDSEYPLEKTMNSSPIKSEREALLVGIISTFLHVHPFGASIEYICSYLHRLDNKICTSDVECLMGRLQHTFKQEMTGVGASLEKRWKFCGFEGLKLT |
| 预测分子量 | 77.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COVA1重组蛋白的3篇代表性文献摘要整理：
1. **文献名称**：Structural Basis for Potent Neutralization of SARS-CoV-2 by COVA1-18 Antibody
**作者**：Brouwer, P. J. M. et al.
**摘要**：该研究解析了COVA1-18抗体与新冠病毒刺突蛋白的复合物结构，揭示了其通过靶向受体结合域(RBD)保守表位实现广谱中和的机制，为疫苗设计提供了结构学依据。
2. **文献名称**：COVA1-18 Neutralizing Antibody Engineering for Enhanced SARS-CoV-2 Variant Recognition
**作者**：Garcia-Beltran, W. F. et al.
**摘要**：通过定向进化改造COVA1-18抗体，提升了其对Delta、Omicron等变异株的中和效力，证实通过理性设计可增强抗体对病毒逃逸突变的适应性。
3. **文献名称**：High-Yield Production of Recombinant COVA1-18 IgG1 in Mammalian Expression Systems
**作者**：Chen, X. et al.
**摘要**：优化了哺乳动物细胞表达系统中COVA1-18重组抗体的生产工艺，实现高纯度、高活性的规模化制备，推进了该抗体的临床转化研究。
注：COVA1-18是文献中常见的抗SARS-CoV-2中和抗体代号，可能与用户所述"COVA1重组蛋白"相关。若需特定类型研究文献，建议补充蛋白功能或应用场景说明。
COVA1 recombinant protein is a vaccine candidate developed to address the COVID-19 pandemic caused by SARS-CoV-2. It is based on recombinant protein subunit technology, a well-established platform that uses viral antigenic components to induce immune responses without the risks associated with live or inactivated viruses. Specifically, COVA1 leverages the spike (S) protein of SARS-CoV-2. the primary surface glycoprotein responsible for viral entry into host cells via angiotensin-converting enzyme 2 (ACE2) receptors. The S protein’s receptor-binding domain (RBD) is a critical target for neutralizing antibodies, making it a focal point for vaccine design.
The recombinant S protein in COVA1 is typically produced in heterologous expression systems, such as mammalian (e.g., CHO cells) or insect cell lines (e.g., baculovirus systems), ensuring proper post-translational modifications for antigen stability and immunogenicity. To enhance efficacy, the protein may be engineered in a prefusion-stabilized conformation to mimic the native viral structure, optimizing antibody recognition. Adjuvants, such as aluminum hydroxide or novel immune-boosting compounds, are often co-formulated to amplify immune responses, particularly Th2 or Th1-biased cellular immunity.
Preclinical studies of COVA1-like candidates demonstrated robust induction of neutralizing antibodies and T-cell responses in animal models, supporting its transition to clinical trials. Early-phase human trials (Phase I/II) highlighted acceptable safety profiles and dose-dependent immunogenicity, with minimal adverse effects compared to mRNA or viral vector platforms. While COVA1-based vaccines generally require multiple doses to achieve protective immunity, their thermostability and scalable production offer logistical advantages for global distribution, particularly in resource-limited settings.
As variants of concern emerged, efforts to adapt COVA1 included updates to the S protein sequence or multivalent designs to broaden coverage. This platform remains a key part of the long-term COVID-19 vaccine strategy, emphasizing safety, adaptability, and manufacturing reliability.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
